BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32077389)

  • 1. Glioblastoma Recurrence Versus Treatment Effect in a Pathology-Documented Series.
    Himes BT; Arnett AL; Merrell KW; Gates MJ; Bhargav AG; Raghunathan A; Brown DA; Burns TC; Parney IF
    Can J Neurol Sci; 2020 Jul; 47(4):525-530. PubMed ID: 32077389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
    Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
    Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution.
    Azoulay M; Santos F; Shenouda G; Petrecca K; Oweida A; Guiot MC; Owen S; Panet-Raymond V; Souhami L; Abdulkarim BS
    J Neurooncol; 2017 May; 132(3):419-426. PubMed ID: 28374095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes and prognostic stratification of patients with recurrent glioblastoma treated with salvage stereotactic radiosurgery.
    Sharma M; Schroeder JL; Elson P; Meola A; Barnett GH; Vogelbaum MA; Suh JH; Chao ST; Mohammadi AM; Stevens GHJ; Murphy ES; Angelov L
    J Neurosurg; 2018 Oct; 131(2):489-499. PubMed ID: 30485180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival.
    Hu LS; Eschbacher JM; Heiserman JE; Dueck AC; Shapiro WR; Liu S; Karis JP; Smith KA; Coons SW; Nakaji P; Spetzler RF; Feuerstein BG; Debbins J; Baxter LC
    Neuro Oncol; 2012 Jul; 14(7):919-30. PubMed ID: 22561797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical, Radiographic, and Pathologic Findings in Patients Undergoing Reoperation Following Radiation Therapy and Temozolomide for Newly Diagnosed Glioblastoma.
    Ellsworth S; Ye X; Grossman SA
    Am J Clin Oncol; 2017 Jun; 40(3):219-222. PubMed ID: 26491903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
    Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
    BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
    Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
    J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laser interstitial thermal therapy for newly diagnosed and recurrent glioblastoma.
    Thomas JG; Rao G; Kew Y; Prabhu SS
    Neurosurg Focus; 2016 Oct; 41(4):E12. PubMed ID: 27690657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up results of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastoma multiforme patients. The importance of MRI information in survival: Single-center experience.
    Lukács G; Tóth Z; Sipos D; Csima M; Hadjiev J; Bajzik G; Cselik Z; Semjén D; Repa I; Kovács Á
    Ideggyogy Sz; 2018 Mar; 71(3-04):95-103. PubMed ID: 29889468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide.
    Faustino AC; Viani GA; Hamamura AC
    Clinics (Sao Paulo); 2020; 75():e1553. PubMed ID: 32935821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicentric non-enhancing lesions in glioblastoma: A retrospective study.
    Benouaich-Amiel A; Khasminsky V; Gal O; Weiss T; Fichman S; Kanner AA; Berkowitz S; Laviv Y; Mandel J; Dudnik E; Siegal T; Yust-Katz S
    J Clin Neurosci; 2021 Mar; 85():20-26. PubMed ID: 33581785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma.
    Xi J; Hassan B; Katumba RGN; Khaddour K; Govindan A; Luo J; Huang J; Campian JL
    BMC Cancer; 2021 Mar; 21(1):285. PubMed ID: 33726710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme.
    Shields LB; Kadner R; Vitaz TW; Spalding AC
    Radiat Oncol; 2013 Apr; 8():101. PubMed ID: 23618500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [
    Koh ES; Gan HK; Senko C; Francis RJ; Ebert M; Lee ST; Lau E; Khasraw M; Nowak AK; Bailey DL; Moffat BA; Fitt G; Hicks RJ; Coffey R; Verhaak R; Walsh KM; Barnes EH; De Abreu Lourenco R; Rosenthal M; Adda L; Foroudi F; Lasocki A; Moore A; Thomas PA; Roach P; Back M; Leonard R; Scott AM
    BMJ Open; 2023 Aug; 13(8):e071327. PubMed ID: 37541751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiographic patterns of relapse in glioblastoma.
    Chamberlain MC
    J Neurooncol; 2011 Jan; 101(2):319-23. PubMed ID: 21052776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: A single-center retrospective series.
    Montemurro N; Fanelli GN; Scatena C; Ortenzi V; Pasqualetti F; Mazzanti CM; Morganti R; Paiar F; Naccarato AG; Perrini P
    Clin Neurol Neurosurg; 2021 Aug; 207():106735. PubMed ID: 34119900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10/ARO 2013-1).
    Oehlke O; Mix M; Graf E; Schimek-Jasch T; Nestle U; Götz I; Schneider-Fuchs S; Weyerbrock A; Mader I; Baumert BG; Short SC; Meyer PT; Weber WA; Grosu AL
    BMC Cancer; 2016 Oct; 16(1):769. PubMed ID: 27716184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
    Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
    J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma.
    Tsien CI; Brown D; Normolle D; Schipper M; Piert M; Junck L; Heth J; Gomez-Hassan D; Ten Haken RK; Chenevert T; Cao Y; Lawrence T
    Clin Cancer Res; 2012 Jan; 18(1):273-9. PubMed ID: 22065084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.